Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Maintenance in HER2-Negative Metastatic Gastric Cancer
NCT03627728Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jun 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started Jun 2018; status: completed.
02
Drugs
regorafenib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03627728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627728.